Anxiety-depression after intravascular ultrasound-guided drug-coated balloon angioplasty dissection: Predictors and 12-month cardiovascular outcomes

Table 6 Clinical and biomarker parameters stratified by anxiety-depression severity, mean ± SD

Parameter	Mild (n = 28)	Moderate (n = 24)	Severe (n = 13)	P for trend
HADS-A score	9.5 ± 1.2	13.0 ± 1.5	17.8 ± 2.0	< 0.001
HADS-D score	9.0 ± 1.0	12.5 ± 1.2	17.2 ± 2.2	< 0.001
12-month MACE (%)	17.9	33.3	46.2	0.005
TLR (%)	10.7	16.7	23.1	0.028
Recurrent angina (%)	17.9	29.2	46.2	0.008
hs-CRP (mg/L)	9.8 ± 3.5	13.5 ± 4.2	16.5 ± 5.2	< 0.001
IL-6 (pg/mL)	7.8 ± 2.5	10.2 ± 3.0	12.8 ± 3.8	< 0.001
Peak hs-TnI (ng/mL)	0.68 ± 0.25	0.88 ± 0.30	1.05 ± 0.38	0.002
NT-proBNP (pg/mL)	325 ± 105	395 ± 120	475 ± 145	0.003
Morning cortisol (nmol/L)	385 ± 85	425 ± 95	465 ± 115	0.005
NLR	4.0 ± 1.2	4.8 ± 1.5	5.8 ± 1.8	0.002
SSRS score	33.2 ± 7.5	29.5 ± 8.0	26.8 ± 6.5	0.008
EQ-5D VAS	65.2 ± 10.5	55.8 ± 11.2	48.5 ± 12.0	< 0.001
Medication adherence (%)	82.5 ± 8.5	72.8 ± 10.2	62.5 ± 12.5	< 0.001
Cardiac rehabilitation participation (%)	71.4	54.2	30.8	0.002

HADS: Hospital Anxiety and Depression Scale; MACE: Major adverse cardiovascular events; TLR: Target lesion revascularization; hs-CRP: High-sensitivity C-reactive protein; IL-6: Interleukin-6; hs-TnI: High-sensitivity troponin I; NT-proBNP: N-terminal pro-B-type natriuretic peptide; NLR: Neutrophil-to-lymphocyte ratio; SSRS: Social Support Rating Scale; EQ-5D VAS: EuroQol five-dimension visual analogue scale.